1. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking.
- Author
-
Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaál J, and Le Foll B
- Subjects
- Animals, Conditioning, Operant drug effects, Cues, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Male, Nicotine administration & dosage, Nicotinic Agonists administration & dosage, Nicotinic Agonists pharmacology, Nitriles therapeutic use, Piperazines agonists, Piperazines therapeutic use, Rats, Rats, Long-Evans, Receptors, Dopamine D3 antagonists & inhibitors, Reinforcement Schedule, Self Administration, Tetrahydroisoquinolines therapeutic use, Tobacco Use Disorder drug therapy, Drug Partial Agonism, Nicotine pharmacology, Nitriles pharmacology, Piperazines pharmacology, Tetrahydroisoquinolines pharmacology
- Abstract
The dopamine D3 receptor (DRD3) has been suggested to be involved in the mechanisms underlying stimulus-controlled drug-seeking behaviour. Ligands acting as DRD3 antagonists (SB 277011-A) or DRD3 partial agonists (BP 897) have shown some promise for reducing the influence of drug-associated cues on motivational behaviour. Here, effects of SB 277011-A and BP 897 were evaluated on cue-induced reinstatement of nicotine-seeking in rats. The effects of BP 897 on nicotine self-administration under a fixed-ratio 5 (FR5) schedule of reinforcement were also evaluated. SB 277011-A (1-10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule. In a control study, rats did not respond to the light stimuli without nicotine delivery, indicating that the responding for the drug-associated cues was induced by the previous pairing of light stimuli with nicotine's effects. These findings validate the role of DRD3 on reactivity to drug-associated stimuli and suggest that the DRD3 antagonist, but perhaps not the DRD3 partial agonist, could be used to prevent relapse in tobacco smokers.
- Published
- 2010
- Full Text
- View/download PDF